当前位置: 首页 » 政策法规 » 国外法规 »(EU) 2015/1041:拒绝批准某些食品健康声称,不涉及降低疾病风险和儿童成长、健康有关的声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health)

(EU) 2015/1041:拒绝批准某些食品健康声称,不涉及降低疾病风险和儿童成长、健康有关的声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health)

扫描二维码 分享好友和朋友圈
放大字体  缩小字体 2015-07-03 09:27:34  来源:欧盟  浏览次数:4238
核心提示:2015年7月1日,欧盟发布委员会条例(EU) 2015/1041,拒绝批准7种食品健康声称,这些食品涉及瓜氨酸-苹果酸盐、橄榄叶水提取物、越蔓梅多酚、叶黄素与玉米黄质混合物、L苏氨酸与多种氨基酸混合物以及两款益生菌混合物。本法规自发布之日起第 20 天生效。
发布单位 暂无 发布文号 (EU) 2015/1041
发布日期 2015-07-01 生效日期 2015-07-21
有效性状态 废止日期 暂无
备注 2015年7月1日,欧盟发布委员会条例(EU) 2015/1041,拒绝批准7种食品健康声称,分别如下:1)瓜氨酸-苹果酸盐可以通过减少乳酸维持ATP水平消除肌肉疲劳;2)每日摄入橄榄叶水提取物多酚有助于降低餐后血糖上升;3)越蔓梅多酚有助于抑制P-菌毛大肠杆菌对尿路细胞的粘附;4)长双歧杆菌LA101,瑞士乳杆菌LA102,乳酸乳球菌LA103和嗜热链球菌LA104的混合物有助于改善肠道;5)长双歧杆菌LA101,瑞士乳杆菌LA102,乳酸乳球菌LA103和嗜热链球菌LA104的混合物可调节肠道运输;6)L-苏氨酸,L-缬氨酸,L-亮氨酸,L-异亮氨酸,L-赖氨酸加吡啶甲酸铬混合物与富含碳水化合物的食物一起食用时,有助于降低血糖的上升;7)在明亮的光线条件下,叶黄素与玉米黄质混合物有助于保持视线清晰和对比。本法规自发布之日起第 20 天生效。
  THE EUROPEAN COMMISSION,
 
  Having regard to the Treaty on the Functioning of the European Union,
 
  Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,
 
  Whereas:
 
  (1)
 
  Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
 
  (2)
 
  Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’, for a scientific assessment, as well as to the Commission and the Member States for information.
 
  (3)
 
  The Authority is to deliver an opinion on the health claim concerned.
 
  (4)
 
  The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.
 
  (5)
 
  Following an application from Biocodex, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of citrulline-malate and faster recovery from muscle fatigue after exercise (Question No EFSA-Q-2013-00659 (2)). The claim proposed by the applicant was worded as follows: ‘Maintenance of ATP levels through reduction of lactates in excess for an improved recovery from muscle fatigue’.
 
  (6)
 
  On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that a health claim on citrulline-malate and faster recovery from muscle fatigue after exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006 had already been assessed by the Authority with an unfavourable outcome (Question No EFSA-Q-2011-00931 (3)). The additional information submitted by the applicant, in the context of Question No EFSA-Q-2013-00659, did not provide evidence that could be used for the scientific substantiation of the claim. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (7)
 
  Following an application from Comvita New Zealand Limited, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of olive (Olea europaea L.) leaf water extract and increase in glucose tolerance (Question No EFSA-Q-2013-00783 (4)). The claim proposed by the applicant was worded as follows: ‘Daily intake of supplemental olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals’.
 
  (8)
 
  On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, the scientific evidence is insufficient to establish a cause and effect relationship between the consumption of olive leaf water extract and increase in glucose tolerance. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (9)
 
  Following an application from Naturex SA, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of Pacran? and defence against bacterial pathogens in the lower urinary tract (Question No EFSA-Q-2013-00889 (5)). The claim proposed by the applicant was worded as follows: ‘Pacran? helps to inhibit the adhesion of P-fimbriated E. coli to the urinary tract cells’.
 
  (10)
 
  On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Pacran? and defence against bacterial pathogens in the lower urinary tract. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (11)
 
  Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort (Question No EFSA-Q-2013-00892 (6)). The claim proposed by the applicant was worded, inter alia, as follows: ‘improves intestinal comfort’.
 
  (12)
 
  On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing gastro-intestinal discomfort. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (13)
 
  Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency (Question No EFSA-Q-2013-00893 (7)). The claim proposed by the applicant was worded, inter alia, as follows: ‘regulates your (intestinal) transit’.
 
  (14)
 
  On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (15)
 
  Following an application from DoubleGood AB, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate and reduction of post-prandial glycaemic responses (Question No EFSA-Q-2013-00756 (8)). The claim proposed by the applicant was worded as follows: ‘Contributes to the reduction of the blood glucose rise when consumed together with a carbohydrate rich meal’.
 
  (16)
 
  On 16 July 2014, the Commission and the Member States received the scientific opinion from the Authority, in which it was stated that the applicant did not provide any evidence that a reduction in post-prandial blood glucose responses achieved by an increase in insulin secretion is a beneficial physiological effect. Consequently, the Authority concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate, which is the subject of the health claim, and a beneficial physiological effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (17)
 
  Following an application from DSM Nutritional Products and Kemin Foods, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of lutein and zeaxanthin and improved vision under bright light conditions (Question No EFSA-Q-2013-00875 (9)). The claim proposed by the applicants was worded as follows: ‘Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions’.
 
  (18)
 
  On 16 July 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of lutein and zeaxanthin and improved vision under bright light conditions. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
 
  (19)
 
  The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
 
  HAS ADOPTED THIS REGULATION:
 
  Article 1
 
  The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
 
  Article 2
 
  This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
 
  This Regulation shall be binding in its entirety and directly applicable in all Member States.
 
  Done at Brussels, 30 June 2015.
 
  For the Commission
 
  The President
 
  Jean-Claude JUNCKER
 
  (1)  OJ L 404, 30.12.2006, p. 9.
 
  (2)  EFSA Journal 2014;12(5):3650.
 
  (3)  EFSA Journal 2012;10(5):2699.
 
  (4)  EFSA Journal 2014;12(5):3655.
 
  (5)  EFSA Journal 2014;12(5):3656.
 
  (6)  EFSA Journal 2014;12(5):3658.
 
  (7)  EFSA Journal 2014;12(5):3659.
 
  (8)  EFSA Journal 2014;12(7):3752.
 
  (9)  EFSA Journal 2014;12(7):3753.

ANNEX

Rejected health claims

Application — Relevant provisions of Regulation (EC) No 1924/2006

Nutrient, substance, food or food category

Claim

EFSA opinion reference

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

Citrulline-malate

Maintenance of ATP levels through reduction of lactates in excess for an improved recovery from muscle fatigue.

Q-2013-00659

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

Olive (Olea europaea L.) leaf water extract

Daily intake of supplemental olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals.

Q-2013-00783

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

Pacran®

Pacran® helps to inhibit the adhesion of P-fimbriated E. coli to the urinary tract cells.

Q-2013-00889

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

A combination of Bifidobacterium longum LA 101,Lactobacillus helveticus LA 102, Lactococcus lactisLA 103 and Streptococcus thermophilus LA 104

Improves intestinal comfort.

Q-2013-00892

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

A combination of Bifidobacterium longum LA 101,Lactobacillus helveticus LA 102, Lactococcus lactisLA 103 and Streptococcus thermophilus LA 104

Regulates your (intestinal) transit.

Q-2013-00893

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

A combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate

Contributes to the reduction of the blood glucose rise when consumed together with a carbohydrate rich meal.

Q-2013-00756

Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.

A combination of lutein and zeaxanthin

Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions.

Q-2013-00875

食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务。
电询:0535-2129301
QQ:2891238009
食品标法圈
实时把握食品标法动态
请扫码关注食品标法圈

声明:

① 凡本网所有原始/编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”。
② 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责。
※ 邮箱:law#foodmate.net(发邮件时请将#换成@) QQ:139307733

 
 
[ 政策法规搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 

 
 
按分类浏览
国家法规 (11359) 国外法规 (3603)
地方法规 (39770) 法规动态 (210)
法规解读 (2623) 其他法规 (506)
推荐国外法规
点击排行
按国家或地区浏览

法规中心  关于我们  广告业务  联系我们  信息服务

Processed in 0.425 second(s), 10 queries, Memory 4.61 M